Angiotensin-Converting Enzyme Inhibition Alters the Fibrinolytic Response to Cardiopulmonary Bypass

Circulation

Volumn 108, Issue 25, 2003, Pages 3079-3083

  Pretorius, Mias ^a,b,c   Murphey, Laine J ^a   McFarlane, Julie A ^a   Vaughan, Douglas E ^a,b   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin; Cardiopulmonary bypass; Inhibitors; Plasminogen activators; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTERIAL GAS; ARTICLE; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FIBRINOLYSIS; HUMAN; INTRAOPERATIVE PERIOD; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZATION; RISK; THROMBOSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOPULMONARY BYPASS; COMBINED MODALITY THERAPY; CORONARY ARTERY BYPASS; FEMALE; FIBRINOLYSIS; GRAFT OCCLUSION, VASCULAR; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0347418932     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000105765.54573.60     Document Type: Article

References (36)

1. Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996;28:616-626.
2. Rifon J, Paramo JA, Panizo C, et al. The increase of plasminogen activator inhibitor activity is associated with graft occlusion in patients undergoing aorto-coronary bypass surgery. Br J Haematol. 1997;99:262-267.
3. Chandler WL, Fitch JC, Wall MH, et al. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost. 1995;74:1293-1297.
4. Moor E, Blomback M, Silveira A, et al. Haemostatic function in patients undergoing coronary artery bypass grafting: perioperative perturbations and relations to saphenous vein graft closure. Thromb Res. 2000;98:39-49.
5. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95:995-1001.
6. Emeis JJ. Perfused rat hindlegs: a model to study plasminogen activator release. Thromb Res. 1983;30:195-203.
7. Brown NJ, Agirbasli MA, Williams GH, et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1 in humans. Hypertension. 1998;32:965-971.
8. Brown NJ, Agirbasli MA, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension. 1999;34:285-290.
9. Brown NJ, Kumar S, Painter CA, et al. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension. 2002;40:859-865.
10. Brown NJ, Abbas A, Byrne D, et al. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation. 2002;105:304-309.
11. Vaughan DE, Rouleau JL, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation. 1997;96:442-447.
12. Wagner A, Herkner H, Schreiber W, et al. Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction. Thromb Haemost. 2002;88:180-185.
13. Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation. 2002;105:457-461.
14. Spiess BD, Vocelka C, Cochran RP, et al. Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 1998;12:299-304.
15. Hunt BJ, Parratt RN, Segal HC, et al. Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg. 1998;65:712-718.
16. Giuliani R, Szwarcer E, Martinez Aquino E, et al. Fibrin-dependent fibrinolytic activity during extracorporeal circulation. Thromb Res. 1991;61:369-373.
17. Paramo JA, Rifon J, Llorens R, et al. Intra- and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery. Haemostasis. 1991;21:58-64.
18. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
19. Brown NJ, Gainer JV, Stein CM, et al. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension. 1999;33:1431-1435.
20. Pretorius M, Rosenbaum D, Vaughan DE, et al. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation, 2003;107:579-585.
21. Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15:316-320.
22. Oshima S, Ogawa H, Mizuno Y, et al. The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction. Am Heart J. 1997;134:961-966.
23. Campbell DJ, Dixon B, Kladis A, et al. Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans. Am J Physiol. 2001;281: R1059-R1070.
24. Cugno M, Nussberger J, Biglioli P, et al. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest. 2001;120:1776-1782.
25. Boldt J, Knothe C, Schindler F, et al. Isolated circulatory response to intravenous administration of the ACE inhibitor enalaprilat. Br J Clin Pharmacol. 1994;37:341-346.
26. Tuman KJ, McCarthy RJ, O'Connor CJ, et al. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth Analg. 1995;80:473-479.
27. Deakin CD, Dalrymple-Hay MJ, Jones P, et al. Effects of angiotensin converting enzyme inhibition on systemic vascular resistance and vasoconstrictor requirements during hypothermic cardiopulmonary bypass. Eur J Cardiothorac Surg. 1998;13:546-550.
28. Licker M, Neidhart P, Lustenberger S, et al. Long-term angiotensin-converting enzyme inhibitor treatment attenuates adrenergic responsiveness without altering hemodynamic control in patients undergoing cardiac surgery. Anesthesiology. 1996;84:789-800.
29. Sakaguchi K, Chai SY, Jackson B, et al. Inhibition of tissue angiotensin converting enzyme: quantitation by autoradiography. Hypertension. 1988;11:230-238.
30. Donahue BS, Gailani D, Higgins MS, et al. Factor V Leiden protects against blood loss and transfusion after cardiac surgery. Circulation. 2003;107:1003-1008.
31. Parr KG, Patel MA, Dekker R, et al. Multivariate predictors of blood product use in cardiac surgery. J Cardiothorac Vasc Anesth. 2003;17:176-181.
32. Despotis GJ, Avidan MS, Hogue CW Jr. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg. 2001:72:S1821-S1831.
33. Boman KO, Jansson JH, Nyhlen KA, et al. Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction. Thromb Haemost. 2002;87:311-316.
34. Wright RA, Flapan AD, Alberti KG, et al. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol. 1994;24:67-73.
35. Shinosaki T, Miyai I, Nomura Y, et al. Mechanisms underlying the ameliorative property of lisinopril in progressive mesangioproliferative nephritis. Nephron. 2002;91:719-729.
36. Zehetgruber M, Beckmann R, Gabriel H, et al. The ACE-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parameters. Thromb Res. 1996;83:143-152.